Advanced search
Publication Cover
Expert Review of Hematology Volume 7, 2014 - Issue 2
Submit an article Journal homepage
344
Views
12
CrossRef citations to date
0
Altmetric
Reviews

An update on type 2B von Willebrand disease

Sameh MikhailDepartment of Hematology, Ohio State University Medical Center, Columbus, OH, USACorrespondence[email protected]
,
Ehab Saad AldinDepartment of Internal Medicine, MedStar Good Samaritan Hospital, Baltimore, MD, USA
,
Michael StreiffDivision of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA
&
Amer ZeidanDivision of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD, USA;Department of Oncology, Johns Hopkins University, Baltimore, MD, USA
Pages 217-231 | Published online: 12 Feb 2014

References

  • Von Willebrand EA. Hereditar pseudohemofili. Finska Lakarsallskapetes Handl. 67(7), 1926 (1926).
  • Gitschier J, Wood WI, Goralka TM et al. Characterization of the human factor VIII gene. Nature 312(5992), 326–330 (1984).
  • Toole JJ, Knopf JL, Wozney JM et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 312(5992), 342–347 (1984).
  • Ginsburg D, Handin RI, Bonthron DT et al. Human von Willebrand factor (vWF): isolation of complementary DNA (cDNA) clones and chromosomal localization. Science 228(4706), 1401–1406 (1985).
  • Lynch DC, Zimmerman TS, Collins CJ et al. Molecula cloning of cDNA for human von Willebrand factor: authentication by a new method. Cell 41(1), 49–56 (1985).
  • Sadler JE, Shelton-Inloes BB, Sorace JM, Harlan JM, Titani K, Davie EW. Cloning and characterization of two cDNAs coding for human von Willebrand factor. Proc. Natl Acad. Sci. USA 82(19), 6394–6398 (1985).
  • Verweij CL, De Vries CJ, Distel B et al. Construction of cDNA coding for human von Willebrand factor using antibody probes for colony-screening and mapping of the chromosomal gene. Nucleic Acids Res. 13(13), 4699–4717 (1985).
  • Ngo KY, Glotz VT, Koziol JA et al. Homozygous and heterozygous deletions of the von Willebrand factor gene in patients and carriers of severe von Willebrand disease. Proc. Natl Acad. Sci. USA 85(8), 2753–2757 (1988).
  • Saiki RK, Gelfand DH, Stoffel S et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239(4839), 487–491 (1988).
  • Kogan SC, Doherty M, Gitschier J. An improved method for prenatal diagnosis of genetic diseases by analysis of amplified DNA sequences. Application to hemophilia A. N. Engl. J. Med. 317(16), 985–990 (1987).
  • Sadler JE, Budde U, Eikenboom JC et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J. Thromb. Haemost. 4(10), 2103–2114 (2006).
  • Federici AB, Canciani MT. Clinical and laboratory versus molecular markers for a correct classification of von Willebrand disease. Haematologica 94(5), 610–615 (2009).
  • Barbui T, Baudo F, Ciavarella N, Group IW. Spectrum of von Willebrand’s disease: a study of 100 cases. Br. J. Haematol. 35(1), 101–112 (1977).
  • Ruggeri ZM. Type IIB von Willebrand disease: a paradox explains how von Willebrand factor works. J. Thromb. Haemost. 2(1), 2–6 (2004).
  • Hollestelle MJ, Thinnes T, Crain K et al. Tissue distribution of factor VIII gene expression in vivo: a closer look. Thromb. Haemost. 86(3), 855–861 (2001).
  • Valentijn KM, Eikenboom J. Weibel-Palade bodies: a window to von Willebrand disease. J. Thromb. Haemost. 11(4), 581–592 (2013).
  • Wagner DD. Cell biology of von Willebrand factor. Annu. Rev. Cell Biol. 6, 217–242 (1990).
  • Verweij CL, Diergaarde PJ, Hart M, Pannekoek H. Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit. EMBO J. 5(8), 1839–1847 (1986).
  • Meitinger T, Meindl A, Bork P et al. Molecular modelling of the Norrie disease protein predicts a cystine knot growth factor tertiary structure. Nat. Genet. 5(4), 376–380 (1993).
  • Zhou YF, Eng ET, Zhu J, Lu C, Walz T, Springer TA. Sequence and structure relationships within von Willebrand factor. Blood 120(2), 449–458 (2012).
  • Mayadas TN, Wagner DD. In vitro multimerization of von Willebrand factor is triggered by low pH. Importance of the pro-polypeptide and free sulfhydryls. J. Biol. Chem. 264, 13497–13503 (1989).
  • Purvis AR, Sadler JE. A covalent oxidoreductase intermediate in propeptide-dependent von Willebrand factor multimerization. J. Biol. Chem. 279(48), 49982–49988 (2004).
  • Mayadas TN, Wagner DD. Vicinal cysteines in the prosequence play a role in von Willebrand factor multimer assembly. Proc. Natl Acad. Sci. USA 89(8), 3531–3535 (1992).
  • Purvis AR, Gross J, Dang LT et al. Two Cys residues essential for von Willebrand factor multimer assembly in the Golgi. Proc. Natl Acad. Sci. USA 104(40), 15647–15652 (2007).
  • Matsuda H, Sugiura S. Ultrastruture of “tubular body” in the endothelial cells of the ocular blood vessels. Invest. Ophthalmol. 9(12), 919–925 (1970).
  • Valentijn KM, Valentijn JA, Jansen KA, Koster AJ. A new look at Weibel-Palade body structure in endothelial cells using electron tomography. J. Struct. Biol. 161(3), 447–458 (2008).
  • Zenner HL, Collinson LM, Michaux G, Cutler DF. High-pressure freezing provides insights into Weibel-Palade body biogenesis. J. Cell Sci. 120(Pt 12), 2117–2125 (2007).
  • Baumgartner-Parzer SM, Wagner L, Reining G et al. Increase by tri-iodothyronine of endothelin-1, fibronectin and von Willebrand factor in cultured endothelial cells. J. Endocrinol. 154(2), 231–239 (1997).
  • Harrison RL, Mckee PA. Estrogen stimulates von Willebrand factor production by cultured endothelial cells. Blood 63(3), 657–664 (1984).
  • Cramer EM, Meyer D, Le Menn R, Breton-Gorius J. Eccentric localization of von Willebrand factor in an internal structure of platelet alpha-granule resembling that of Weibel-Palade bodies. Blood 66(3), 710–713 (1985).
  • Rickles FR, Hoyer LW, Rick ME, Ahr DJ. The effects of epinephrine infusion in patients with von Willebrand’s disease. J. Clin. Invest. 57(6), 1618–1625 (1976).
  • Mannucci PM, Ruggeri ZM, Pareti FI, Capitanio A. 1-deamino-8-d-arginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands’ diseases. Lancet 1(8017), 869–872 (1977).
  • Giblin JP, Hewlett LJ, Hannah MJ. Basal secretion of von Willebrand factor from human endothelial cells. Blood 112(4), 957–964 (2008).
  • Nachman RL, Jaffe EA. Subcellular platelet factor VIII antigen and von Willebrand factor. J. Exp. Med. 141(5), 1101–1113 (1975).
  • Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87(10), 4223–4234 (1996).
  • Tsai HM. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87(10), 4235–4244 (1996).
  • Dong JF, Moake JL, Nolasco L et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100(12), 4033–4039 (2002).
  • Reiter RA, Knöbl P, Varadi K, Turecek PL. Changes in von Willebrand factor-cleaving protease (ADAMTS13) activity after infusion of desmopressin. Blood 101(3), 946–948 (2003).
  • Bowen DJ, Collins PW. Insights into von Willebrand factor proteolysis: clinical implications. Br. J. Haematol. 133(5), 457–467 (2006).
  • Pruss CM, Notley CR, Hegadorn CA, O’Brien LA, Lillicrap D. ADAMTS13 cleavage efficiency is altered by mutagenic and, to a lesser extent, polymorphic sequence changes in the A1 and A2 domains of von Willebrand factor. Br. J. Haematol. 143(4), 552–558 (2008).
  • Sugimoto M, Mohri H, Mcclintock RA, Ruggeri ZM. Identification of discontinuous von Willebrand factor sequences involved in complex formation with botrocetin. A model for the regulation of von Willebrand factor binding to platelet glycoprotein Ib. J. Biol. Chem. 266(27), 18172–18178 (1991).
  • Jenkins PV, Pasi KJ, Perkins SJ. Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand’s disease. Blood 91(6), 2032–2044 (1998).
  • Miura S, Li CQ, Cao Z, Wang H, Wardell MR, Sadler JE. Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion. J. Biol. Chem. 275(11), 7539–7546 (2000).
  • Cruz MA, Yuan H, Lee JR, Wise RJ, Handin RI. Interaction of the von Willebrand factor (vWF) with collagen. Localization of the primary collagen-binding site by analysis of recombinant vWF a domain polypeptides. J. Biol. Chem. 270(18), 10822–10827 (1995).
  • Koppelman SJ, Van Hoeij M, Vink T et al. Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood 87(6), 2292–2300 (1996).
  • Foster PA, Fulcher CA, Marti T, Titani K, Zimmerman TS. A major factor VIII binding domain resides within the amino-terminal 272 amino acid residues of von Willebrand factor. J. Biol. Chem. 262(18), 8443–8446 (1987).
  • Vicente V, Houghten RA, Ruggeri ZM. Identification of a site in the alpha chain of platelet glycoprotein Ib that participates in von Willebrand factor binding. J. Biol. Chem. 265(1), 274–280 (1990).
  • Fay PJ, Coumans JV, Walker FJ. von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J. Biol. Chem. 266(4), 2172–2177 (1991).
  • Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J. Clin. Invest. 82(4), 1236–1243 (1988).
  • Ruggeri ZM, Ware J. von Willebrand factor. FASEB J. 7(2), 308–316 (1993).
  • Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 94(5), 657–666 (1998).
  • Dopheide SM, Maxwell MJ, Jackson SP. Shear-dependent tether formation during platelet translocation on von Willebrand factor. Blood 99(1), 159–167 (2002).
  • Uff S, Clemetson JM, Harrison T, Clementson KJ, Emsley J. Crystal structure of the platelet glycoprotein Ib (alpha) N-terminal domain reveals an unmasking mechanism for receptor inactivation. J. Biol. Chem. 277(38), 35657–35663 (2002).
  • Favaloro EJ. Phenotypic identification of platelet-type von Willebrand disease and its discrimination from type 2B von Willebrand disease: a question of 2B or not 2B? A story of nonidentical twins? Or two sides of a multidenominational or multifaceted primary-hemostasis coin? Semin. Thromb. Hemost. 34(1), 113–127 (2008).
  • Dumas JJ, Kumar R, Mcdonagh T et al. Crystal structure of the wild-type von Willebrand factor A1-glycoprotein Ibalpha complex reveals conformation differences with a complex bearing von Willebrand disease mutations. J. Biol. Chem. 279(22), 23327–23334 (2004).
  • Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu. Rev. Biochem. 67, 395–424 (1998).
  • Ginsburg D, Sadler JE. Von Willebrand disease: a database of point mutations, insertions, and deletions. For the consortium on von Willebrand factor mutations and polymorphisms, and the Subcommittee on von Willebrand factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb. Haemost. 69(2), 177–184 (1993).
  • Budde U, Schneppenheim R. Von Willebrand factor and von Willebrand disease. Rev. Clin. Exp. Hematol. 5(4), 335–368 (2001).
  • Fujimura Y, Titani K, Holland LZ et al. Von Willebrand factor. A reduced and alkylated 52/48-kDa fragment beginning at amino acid residue 449 contains the domain interacting with platelet glycoprotein Ib. J. Biol. Chem. 261(1), 381–385 (1986).
  • Randi AM, Rabinowitz I, Mancuso DJ, Mannucci PM, Sadler JE. Molecular basis of von Willebrand disease type IIB. Candidate mutations cluster in one disulfide loop between proposed platelet glycoprotein Ib binding sequences. J. Clin. Invest. 87(4), 1220–1226 (1991).
  • Sadler JE. Von Willebrand factor. J. Biol. Chem. 266(34), 22777–22780 (1991).
  • Ruggeri ZM, Pareti FI, Mannucci PM, Ciavarella N, Zimmerman TS. Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand’s disease. N. Engl. J. Med. 302(19), 1047–1051 (1980).
  • Huizinga EG, Tsuji S, Romijn RA et al. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science 297(5584), 1176–1179 (2002).
  • Ginsburg D, Bowie EJ. Molecular genetics of von Willbrand disease. Blood 79(10), 2507–2519 (1992).
  • Nurden P, Debili N, Vainchenker W et al. Impaired megakaryocytopoiesis in type 2B von Willebrand disease with severe thrombocytopenia. Blood 108(8), 2587–2595 (2006).
  • Milton JG, Frojmovic MM. Invaginated plasma membrane of human platelets: evagination and measurement in normal and ‘giant’ platelets. J. Lab. Clin. Med. 93(1), 162–170 (1979).
  • Jackson SC, Sinclair GD, Cloutier S, Duan Z, Rand ML, Poon MC. The Montreal platelet syndrome kindred has type 2B von Willebrand disease with the VWF V1316M mutation. Blood 113(14), 3348–3351 (2009).
  • Casari C, Du V, Wu Y-P et al. Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B-associated thrombocytopenia. Blood 122(16), 2893–2902 (2013).
  • Federici AB, Mannucci PM, Castaman G et al. Clinical and molecular predictors of thromboytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 113(3), 526–534 (2009).
  • Tosetto A, Rodeghiero F, Castaman G et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J. Thromb. Haemost. 4(4), 766–773 (2006).
  • Rayes J, Hommais A, Legendre P et al. Effect of von Willebrand disease type 2B and type 2M mutations on the susceptibility of von Willebrand factor to ADAMTS-13. J. Thromb. Haemost. 5(2), 321–328 (2007).
  • Castaman G, Goodeve A, Eikenboom J; European Group on von Willebrand disease (EUVWD). Principles of care for the diagnosis and treatment of von Willebrand disease. Haematologica 98(5), 667–674 (2013).
  • Cooney KA, Nichols WC, Bruck ME et al. The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GpIb binding domain. J. Clin. Invest. 87(4), 1227–1233 (1991).
  • Cooney KA, Lyons SE, Ginsburg D. Functional analysis of a type IIB von Willebrand disease missense mutation: increased binding of large von Willebrand factor multimers to platelets. Proc. Natl Acad. Sci. USA 89(7), 2869–2872 (1992).
  • Randi A, Tuley E, Jorieux S, Rabinowitz I, Sadler J. A missense mutation (R578Q) in von Willebrand disease(vWD) type IIB affects von Willebrand factor (vWF) binding to GPIB but not to collagen or heparin: Studies with recombinant vWF. Blood 78, 179a (1991).
  • Ware J, Dent JA, Azuma H et al. Identification of a point mutation in type IIB von Willebrand disease illustrating the regulation of von Willebrand factor affinity for the platelet membrane glycoprotein Ib-IX receptor. Proc. Natl Acad. Sci. USA 88(7), 2946–2950 (1991).
  • Murray EW, Giles AR, Lillicrap D. Recurring mutations at CpG dinucleotides and germ line mosaicism in the von Willebrand factor (vWF) gene as a cause of type IIB von Willebrand’s disease (vWD). Am. J. Hum. Genet. 29(4), 199 (1991).
  • Murray EW, Giles AR, Lillicrap D. Germ-line mosaicism for a valine-to-methionine substitution at residue 553 in the glycoprotein Ib-binding domain of von Willebrand factor, causing type IIB von Willebrand disease. Am. J. Hum. Genet. 50(1), 199–207 (1992).
  • Holmberg L, Donner M, Dahlback B, Nilsson IM. Apparently recessive IIB von Willebrand disease (vWD) is caused by de novo mutations (ARG543--TRP; VAL551--LEU). Blood 78, 150a (1991).
  • Sugiura I, Matsushita T, Tanimoto M et al. The molecular defects in Japanese patients with type II von Willebrand disease. Thromb. Haemost. 65, 763 (1991).
  • Ribba AS, Lavergne JM, Bahnak BR, Derlon A, Pietu G, Meyer D. Duplication of a methionine within the glycoprotein Ib binding domain of von Willebrand factor detected by denaturing gradient gel electrophoresis in a patient with type IIB von Willebrand disease. Blood 78(7), 1738–1743 (1991).
  • Mathew P, Greist A, Maahs JA, Lichtenberg EC, Shapiro AD. Type 2B vWD: the varied clinical manifestations in two kindreds. Haemophilia 9(1), 137–144 (2003).
  • Othman M, Favaloro EJ. Genetics of type 2B von Willebrand disease: “true 2B,” “tricky 2B,” or “not 2B.” What are the modifiers of the phenotype? Semin. Thromb. Hemost. 34(6), 520–531 (2008).
  • Casonato A, Sartorello F, Pontara E et al. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis. Thromb. Haemost. 98(6), 1182–1187 (2007).
  • Takimoto Y, Imanaka F. Type 2B Hiroshima: a variant of von Willebrand disease characterized by chronic thrombocytopenia and the presence of all von Willebrand factor multimers in plasma. Int. J. Hematol. 70(2), 127–131 (1999).
  • Saba HI, Saba SR, Dent J, Ruggeri ZM, Zimmerman TS. Type IIB Tampa: a variant of von Willebrand disease with chronic thrombocytopenia, circulating platelet aggregates, and spontaneous platelet aggregation. Blood 66(2), 282–286 (1985).
  • Moll S, Lazarowski AR, 2nd WG. Giant platelet disorder in a patient with type 2B von Willebrand’s disease. Am. J. Hematol. 57(1), 62–67 (1998).
  • Loffredo G, Baronciani L, Noris P, Menna F, Federici AB, Balduini CL. Von Willebrand disease type 2B must be always considered in the differential diagnosis of genetic thrombocytopenias with giant platelets. Platelets 17(3), 149–152 (2006).
  • Hilbert L, Nurden P, Caron C et al. Type 2N von Willebrand disease due to compound heterozygosity for R854Q and a novel R763G mutation at the cleavage site of von Willebrand factor propeptide. Thromb. Haemost. 96(3), 290–294 (2006).
  • Rendal E, Penas N, Larrabeiti B et al. Type 2B von Willebrand’s disease due to Val1316Met mutation. Heterogeneity in the same sibship. Ann. Hematol. 80(6), 354–360 (2001).
  • Rabinowitz I, Randi AM, Schindler KS, Tuley EA, Rustagi PK, Sadler JE. Type IIB mutation His-505-->Asp implicates a new segment in the control of von Willebrand factor binding to platelet glycoprotein Ib. J. Biol. Chem. 268(27), 20497–20501 (1993).
  • Roland K, Rapson D, Lillicrap D, James P. The value of genetic testing for type 2B Von Willebrand disease. Clin. Lab. Haematol. 28(1), 17–21 (2006).
  • Hilbert L, Gaucher C, De Romeuf C, Horellou MH, Vink T, Mazurier C. Leu 697-->Val mutation in mature von Willebrand factor is responsible for type IIB von Willebrand disease. Blood 83(6), 1542–1550 (1994).
  • Levy G, Ginsburg D. Getting at the variable expressivity of von Willebrand disease. Thromb. Haemost. 2001(86), 1 (2001).
  • Szántó T, Schlammadinger A, Salles I et al. Type 2B von Willebrand disease in seven individuals from three different families: phenotypic and genotypic characterization. Thromb. Haemost. 98(1), 251–254 (2007).
  • Werner EJ. von Willebrand disease in children and adolescents. Pediatr. Clin. North Am. 43(3), 683–707 (1996).
  • Schneppenheim R, Budde U, Beutel K et al. Response to DDAVP in children with von Willebrand disease type 2. Hamostaseologie 29(2), 143–148 (2009).
  • Schneppenheim R, Thomas KB, Sutor AH. Von Willebrand disease in childhood. Semin. Thromb. Hemost. 21(3), 261–275 (1995).
  • National Heart Lung, and Blood Institute. The Diagnosis, Evaluation, and Management of von Willebrand Disease. National Institute of Health, Bethesda, MD, USA (2007).
  • Rodeghiero F, Tosetto A, Abshire T et al. ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J. Thromb. Haemost. 8(9), 2063–2065 (2010).
  • Tosetto A, Castaman G, Rodeghiero F. Bleeding scores in inherited bleeding disorders: clinical or research tools? Haemophilia 14(3), 415–422 (2008).
  • Rodeghiero F, Castaman G, Tosetto A et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J. Thromb. Haemost. 3(12), 2619–2616 (2005).
  • Tosetto A, Castaman G, Rodeghiero F. Evidence-based diagnosis of type 1 von Willebrand disease: a Bayes theorem approach. Blood 111(8), 3998–4003 (2008).
  • Michiels JJ, Berneman Z, Gadisseur A et al. Classification and characterization of hereditary types 2A, 2B, 2C, 2E, 2M, 2N, and 2U (unclassifiable) von Willebrand disease. Clin. Appl. Thromb. Hemost. 12(4), 397–420 (2006).
  • Michiels JJ, Van De Velde A, Van Vliet HH, Van Der Planken M, Schroyens W, Berneman Z. Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications. Semin. Thromb. Hemost. 28(2), 111–132 (2002).
  • Gadisseur A, Berneman Z, Schroyens W, Michiels JJ. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio. Acta Haematol. 123(2–3), 128–138 (2009).
  • Casonato A, Daidone V, Padrini R. Assessment of von Willebrand factor propeptide improves the diagnosis of von Willebrand disease. Semin. Thromb. Hemost. 37(5), 456–463 (2011).
  • Jantunen E. Inherited giant platelet disorders. Eur. J. Haematol. 53(4), 191–196 (1994).
  • Othman M. Platelet-type von Willebrand disease and type 2B von Willebrand disease: a story of nonidentical twins when two different genetic abnormalities evolve into similar phenotypes. Semin. Thromb. Hemost. 33(8), 780–786 (2007).
  • López JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier syndrome. Blood 91(12), 4397–4418 (1998).
  • Franchini M, Montagnana M, Lippi G. Clinical, laboratory and therapeutic aspects of platelet-type von Willebrand disease. Int. J. Lab. Hematol. 30(2), 91–94 (2008).
  • Favaloro EJ. 2B or not 2B? Differential identification of type 2B, versus pseudo-von Willebrand disease. Br. J. Haematol. 135(1), 141–142 (2006).
  • Enayat MS, Guilliatt AM, Lester W, Wilde JT, Williams MD, Hill FG. Distinguishing between type 2B and pseudo-von Willebrand disease and its clinical importance. Br. J. Haematol. 133(6), 664–666 (2006).
  • Scott JP, Montgomery RR. The rapid differentiation of type IIb von Willebrand’s disease from platelet-type (pseudo-) von Willebrand’s disease by the “neutral” monoclonal antibody binding assay. Am. J. Clin. Pathol. 96(6), 723–728 (1991).
  • Sadler JE, Mannucci PM, Berntorp E et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb. Haemost. 84(2), 160–174 (2000).
  • Federici AB, Castaman G, Mannucci PM, (Aice) IaOHC. Guidelines for the diagnosis and management of von Willebrand disease in Italy. Haemophilia 8(5), 607–621 (2002).
  • Pasi KJ, Collins PW, Keeling DM et al. Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors’ Organization. Haemophilia 10(3), 218–231 (2004).
  • Federici AB. Clinical diagnosis of von Willebrand disease. Haemophilia 10( Suppl. 4), 169–176 (2004).
  • Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br. J. Haematol. 111(4), 1236–1239 (2000).
  • Silwer J. Von Willebrand's disease in Sweden. Acta Paediatr. Scand. Suppl. 238, 1–159 (1973).
  • Sramek A, Eikenboom JC, Briet E, Vandenbrouke JP, Rosendaal FR. Usefulness of patient interview in bleeding disorders. Arch. Intern. Med. 155(13), 1409–1415 (1995).
  • Drews CD, Dilley AB, Lally C, Beckman MG, Evatt B. Screening questions to identify women with von Willebrand disease. J. Am. Med. Womens Assoc. 57(4), 217–218 (2002).
  • Mauser Bunschoten EP, Van Houwelingen JC, Sjamsoedin Visser EJ, Van Dijken PJ, Kok AJ, Sixma JJ. Bleeding symptoms in carriers of hemophilia A and B. Thromb. Haemost. 59(3), 349–352 (1988).
  • Woods AI, Meschengieser SS, Blanco AN et al. Clinical features and laboratory patterns in a cohort of consecutive Argentinian patients with von Willebrand's disease. Haematologica 86(4), 420–427 (2001).
  • Ziv O, Ragni MV. Bleeding manifestations in males with von Willebrand disease. Haemophilia 10(2), 162–168 (2004).
  • Mannucci PM, Franchini M, Castaman G, Federici AB, Italian Association of Hemophilia Centers. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus. 7(2), 117–126 (2009).
  • Casonato A, Steffan A, Pontara E et al. Post-DDAVP thrombocytopenia in type 2B von Willebrand disease is not associated with platelet consumption: failure to demonstrate glycocalicin increase or platelet activation. Thromb. Haemost. 81(2), 224–228 (1999).
  • Casonato A, Pontara E, Dannhaeuser D et al.Re-evaluation of the therapeutic efficacy of DDAVP in type IIB von Willebrand's disease. Blood Coagul. Fibrinolysis 5(6), 959–964 (1994).
  • Fowler WE, Berkowitz LR, Roberts HR. DDAVP for type IIB von Willebrand disease. Blood 74(5), 1859–1860 (1989).
  • Michiels JJ, Gadisseur A, Budde U et al. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences. Semin. Thromb. Hemost. 31(5), 577–601 (2005).
  • Makris M, Colvin B, Gupta V, Shields ML, Smith MP. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb. Haemost. 88(3), 387–388 (2002).
  • Mannucci PM, Chediak J, Hanna W et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 99(2), 450–456 (2002).
  • Güth U, Tsakiris DA, Reber A, Holzgreve W, Hösli I. [Management of patients with Type 2B von Willebrand's disease during delivery and puerperium]. Z Geburtshilfe. Neonatol. 206(4), 151–155 (2002).
  • Foster PA. The reproductive health of women with von Willebrand Disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb. Haemost. 74(2), 784–790 (1995).
  • Pacheco LD, Costantine MM, Saade GR, Mucowski S, Hankins GDV, Sciscione AC. von Willebrand disease and pregnancy: a practical approach for the diagnosis and treatment. Am. J. Obstet. Gynecol. 203(3), 194–200 (2010).
  • Todd RFR, Gitlin SD, Burns LJ, Committee on Training Programs. Subspeciality training in hematology and oncology, 2003: results of a survey of training program directors conducted by the American Society of Hematology. Blood 103(12), 4383–4388 (2004).
  • Goudemand J, Negrier C, Ounnoughene N, Sultan Y. Clinical management of patients with von Willebrand's disease with a VHP vWF concentrate: the French experience. Haemophilia 4( Suppl. 3), 48–52 (1998).
  • Castaman G, Montgomery RR, Meschengieser SS, Haberichter SL, Woods AI, Lazzari MA. von Willebrand's disease diagnosis and laboratory issues. Haemophilia 16( Suppl. 5), 67–73 (2010).
  • Flood VH, Gill JC, Morateck PA et al.Gain-of-function GPIb ELISA assay for VWF activity in the zimmerman program for the molecular and clinical biology of VWD. Blood 117(6), e67–e74 (2011).
  • Flood VH, Gill JC, Friedman KD et al. Collagen binding provides a sensitive screen for variant von Willebrand disease. Clin. Chem. 59(4), 684–691 (2013).
  • Castaman G, Lattuada A, Mannucci PM, Rodeghiero F. Factor VIII:C increases after desmopressin in a subgroup of patients with autosomal recessive severe von Willebrand disease. Br. J. Haematol. 89(1), 147–151 (1995).
  • Castaman G, Rodeghiero F. Desmopressin and type II B von Willebrand disease. Haemophilia 2(2), 73–77 (1996).
  • De La Fuente B, Kasper CK, Rickles FR, Hoyer LW. Response of patients with mild and moderate hemophilia A and von Willebrand's disease to treatment with desmopressin. Ann. Intern. Med. 103(1), 6–14 (1985).
  • Revel-Vilk S, Schmugge M, Carcao MD, Blanchette P, Rand ML, Blanchette VS. Desmopressin (DDAVP) responsiveness in children with von Willebrand disease. J. Pediatr. Hematol. Oncol. 25(11), 874–879 (2003).
  • Mariana G, Ciavarella N, Mazzucconi MG et al.Evaluation of the effectiveness of DDAVP in surgery and in bleeding episodes in haemophilia and von Willebrand's disease. A study on 43 patients. Clin. Lab. Haematol. 6(3), 229–238 (1984).
  • Nitu-Whalley IC, Griffioen A, Harrington C, Lee CA. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease. Am. J. Hematol. 66(4), 280–284 (2001).
  • Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb. Haemost. 87(2), 224–230 (2002).
  • Federici AB, Sacco R, Stabile F, Carpenedo M, Zingaro E, Mannucci PM. Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases. Haemophilia 6(2), 71–77 (2000).
  • Jimenez-Yuste V, Prim MP, De Diego JI et al. Otolaryngologic surgery in children with von Willebrand disease. Arch. Otolaryngol. Head Neck Surg. 128(12), 1365–1368 (2002).
  • Kreuz W, Mentzer D, Becker S, Scharrer I, Kornhuber B. Haemate-P® in children with von Willebrand's disease. Haemostasis 24(5), 304–310 (1994).
  • Thompson AR, Gill JC, Ewenstein BM, Mueller-Velten G, Schwartz BA; Humate-P Study Group. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P®). Haemophilia 10(1), 42–51 (2004).
  • Lethagen S, Frick K, Sterner G. Antidiuretic effect of desmopressin given in hemostatic dosages to healthy volunteers. Am. J. Hematol. 57(2), 153–159 (1998).
  • Amesse LS, Pfaff-Amesse T, Leonardi R, Uddin D, French JA 2nd. Oral contraceptives and DDAVP nasal spray: patterns of use in managing vWD-associated menorrhagia: a single-institution study. J. Pediatr. Hematol. Oncol. 27(7), 357–363 (2005).
  • Rodeghiero F, Castaman G, Di Bona E, Ruggeri M, Lombardi R, Mannucci PM. Hyper-responsiveness to DDAVP for patients with type I von Willebrand's disease and normal intraplatelet von Willebrand factor. Eur. J. Haematol. 40(2), 163–167 (1988).
  • Saulnier J, Marey A, Horrellou MH et al. Evaluation of desmopressin for dental extractions in patients with hemostatic disorders. Oral Surg. Oral Med. Oral Pathol. 77(1), 6–12 (1994).
  • Rakocz M, Mazar A, Varon D, Spierer S, Blinder D, Martinowitz U. The use of fibrin glue. Oral Surg. Oral Med. Oral Pathol. 75(3), 280–282 (1993).
  • Rodeghiero F, Castaman G, De Bona E, Ruggeri M. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. Blood 74(6), 1997–2000 (1989).
  • Allen GC, Armfield DR, Bontempo FA, Kingsley LA, Goldstein NA, Post JC. Adenotonsillectomy in children with von Willebrand disease. Arch. Otolaryngol. Head Neck Surg. 125(5), 547–551 (1999).
  • Derkay CS, Werner E, Plotnick E. Management of children with von Willebrand disease undergoing adenotonsillectomy. Am. J. Otolaryngol. 17(3), 172–177 (1996).
  • Manno CS, Butler RB, Farace L, Cohen AR. Successful management of patients with type 1 von Willebrand's disease with desmopressin acetate for tonsillectomy (abstract). Haemophilia 4, 288 (1998).
  • Shah SB, Lalwani AK, Koerper MA. Perioperative management of von Willebrand's disease in otolaryngologic surgery. Laryngoscope 108(1 Pt 1), 32–36 (1998).
  • Dobrkovska A, Krzensk U, Chediak JR. Pharmacokinetics, efficacy and safety of Humate-P® in von Willebrand disease. Haemophilia ( 4 Suppl. 3), 33–39 (1998).
  • Hanna WT, Bona RD, Zimmerman CE, Carta CA, Hebert GZ, Rickles FR. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease. Thromb. Haemost. 71(2), 173–179 (1994).
  • Lubetsky A, Schulman S, Varon D et al. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P®) in patients with von Willebrand disease. Thromb. Haemost. 81(2), 229–233 (1999).
  • Michiels JJ, Berneman ZN, Van Der Planken M, Schroyens W, Budde U, Van Vliet HH. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P). Blood Coagul. Fibrinolysis 15(4), 323–330 (2004).
  • Scharrer I, Vigh T, Aygören-Pürsün E. Experience with Haemate-P in von Willebrand's disease in adults. Haemostasis 24(5), 298–303 (1994).
  • Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA; Humate-P Study Group. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P®): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia 9(6), 688–695 (2003).
  • Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb. Haemost. 88(3), 378–379 (2002).
  • Kadir RA. Women and inherited bleeding disorders: pregnancy and delivery. Semin. Hematol. 36( 3 Suppl. 4), 28–35 (1999).
  • Kouides PA. Obstetric and gynaecological aspects of von Willebrand disease. Best Pract. Res. Clin. Haematol. 14(2), 381–399 (2001).
  • Mannucci PM. Treatment of von Willebrand's disease. N. Engl. J. Med. 351(7), 683–694 (2004).
  • Greer IA, Lowe GD, Walker JJ, Forbes CD. Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies. Br. J. Obstet. Gynaecol. 98(9), 909–918 (1991).
  • Kadir RA, Lee CA, Sabin CA, Pollard D, Economides DL. Pregnancy in women with von Willebrand's disease or factor XI deficiency. Br. J. Obstet. Gynaecol. 105(3), 314–321 (1998).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.